1110020G09Rik Inhibitors
Chemical inhibitors of the protein 1110020G09Rik act through various signaling pathways to inhibit its function. Staurosporine is a broad-spectrum kinase inhibitor that can prevent the phosphorylation of this protein, an essential post-translational modification necessary for its function. Similarly, dasatinib and PP2 specifically inhibit Src family kinases, which, if involved in the activation of 1110020G09Rik, would lead to its inhibition. Rapamycin targets the mTOR kinase within the PI3K/AKT pathway, a critical regulator of cell growth and proliferation. By inhibiting mTOR, rapamycin can suppress the functions of 1110020G09Rik if they are linked to this pathway. LY294002 and wortmannin also inhibit the PI3K/AKT pathway, but they act upstream of mTOR, preventing the activation of AKT and subsequent downstream effects, which could include the functional regulation of 1110020G09Rik.
Further inhibitors that can affect 1110020G09Rik include PD98059 and U0126, both of which target MEK1/2 in the MAPK/ERK pathway. This pathway is known for its role in cell proliferation and differentiation, and its inhibition can lead to the attenuation of 1110020G09Rik activity if it is associated with these cellular processes. SB203580 and SP600125 inhibit the p38 MAP kinase and JNK, respectively, both part of the MAP kinase family. If 1110020G09Rik relies on signaling through these kinases, its function would be inhibited by these chemicals. ZM-447439 inhibits Aurora kinases, which have key roles during cell division; inhibition of these kinases can impact 1110020G09Rik if its function is cell cycle-dependent. Lastly, venetoclax inhibits Bcl-2, which is involved in the regulation of apoptosis. Inhibition of Bcl-2 can affect 1110020G09Rik function if it is involved in cell survival pathways. Each of these inhibitors can lead to the inhibition of 1110020G09Rik by targeting different regulatory mechanisms within the cell.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. Considering 1110020G09Rik's function is dependent on its phosphorylation state, staurosporine can inhibit this protein by preventing its phosphorylation through kinase inhibition. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, a key kinase in the PI3K/AKT pathway, which is involved in cell growth and proliferation. Inhibition of mTOR by rapamycin leads to a decrease in cellular activities dependent on this pathway, potentially inhibiting the function of 1110020G09Rik if it is involved in these processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that can inhibit the PI3K/AKT pathway, reducing AKT phosphorylation and activation. By inhibiting this pathway, LY294002 can suppress the function of 1110020G09Rik if the protein's activity is regulated by PI3K/AKT signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor with a mechanism similar to LY294002. It can inhibit the PI3K/AKT pathway, which may lead to functional inhibition of 1110020G09Rik by reducing signaling through this pathway if the protein's activity is associated with it. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor that blocks the MAPK/ERK pathway by inhibiting MEK1/2. Since the MAPK/ERK pathway is involved in cell proliferation and differentiation, inhibition of this pathway by PD98059 can lead to inhibition of 1110020G09Rik function if it is regulated by or involved in this signaling cascade. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 also inhibits MEK1/2 in the MAPK/ERK pathway, which may result in functional inhibition of 1110020G09Rik if the protein's activity is modulated by this pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is an inhibitor of p38 MAP kinase. If 1110020G09Rik relies on p38 MAPK signaling for its function, SB203580 inhibition of p38 MAPK would result in the functional inhibition of 1110020G09Rik. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). If the JNK pathway modulates the activity of 1110020G09Rik, inhibition by SP600125 would result in functional inhibition of the protein. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor. If Src kinase activity is necessary for the function of 1110020G09Rik, then dasatinib would inhibit this protein by inhibiting Src kinases. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is another Src family kinase inhibitor. It can inhibit the function of 1110020G09Rik by inhibiting Src family kinases, assuming Src kinase activity is required for the protein's function. | ||||||